Roche's Invirase (saquinavir) expanded access lottery to be managed by Parexel.
ROCHE INVIRASE (SAQUINAVIR) EXPANDED ACCESS LOTTERY MANAGED BY PAREXEL will register HIV-positive patients to be selected for 2,280 available U.S. slots to receive the protease inhibitor, Hoffmann-La Roche announced June 21. Patients who have failed prior antiviral treatment may be registered by their physicians until 5 p.m. July 21, after which a lottery is to be conducted. Invirase will be shipped free of charge to the lottery selectees in August.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth